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ABSTRACT 
Background:  Various studies have shown that people with serious mental illness have an 
increased risk for metabolic syndrome with prevalence ranging from 28.7% to 60%. Given the 
amount of evidence suggesting a link between clozapine and metabolic syndrome, several 
guidelines have recommended regular clinical monitoring of metabolic syndrome in patients 
on clozapine. 
Aim: To determine the screening, prevalence and associated risk factors of metabolic 
disorders in forensic patients with schizophrenia spectrum disorders who are on clozapine 
(study group) compared to patients on haloperidol (control group). 
Methods:  It is a retrospective, folder review of forensic male adult patients at Valkenberg 
Hospital, Observatory Cape Town. 
Results: There were 45 patients in the study group and 23 patients in the control group. Eight 
patients (17.8%) in the study group (Clozapine) met criteria for metabolic syndrome according 
to the NCEP-ATP III criteria and none of the patients in the control group (Haloperidol) did (χ2 
(1) = 4.441, p = .035 V = .257).  Patients who had a diagnosis of schizoaffective disorder were 
also on mood stabilisers in addition to clozapine. Again, while none of the patients on 
Haloperidol met the criteria for Metabolic syndrome, 6 (24%) of the 25 patients on concurrent 
Clozapine and sodium valproate did, (χ2 (1) = 6.051, p = .023 V = .359). 
In terms of metabolic disorders, a significantly higher proportion of patients in the study 
group has hypertension and hyperlipidaemia (p = .003 and p = .021 respectively). Less than 
25% of all patients were fully screened for metabolic syndrome. There was a very low rate of 
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screening of blood tests: fasting glucose, total cholesterol, trigylcerides, High Density 
Lipoprotein(HDL) or Low-Density Lipoprotein (LDL).  
Conclusion: The prevalence of metabolic syndrome was higher in the clozapine group than 
haloperidol group, which is unsurprising since clozapine is usually associated with a higher 
risk of metabolic syndrome. However, the prevalence on metabolic syndrome in this study 
sample was relatively low compared to other studies. This could be due to the low rate of 
screening of each criteria of metabolic syndrome. Screening for metabolic syndrome should 
be regularly performed by health professionals in patients with serious mental illness. Further 
studies are needed to investigate the risk of metabolic syndrome for patients who are on a 
combination of clozapine and mood stabilisers. 
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CHAPTER 1: LITERATURE REVIEW AND INTRODUCTION 
LITERATURE REVIEW 
A literature review was conducted to critically analyse the screening of metabolic syndrome 
in severe mental illness. The author has done the review under the headings of 1. 
Cardiovascular mortality and severe mental illness 2. Definition of metabolic syndrome 3. 
Mechanisms of metabolic syndrome 4. Prevalence of metabolic syndrome and its associated 
risk factors 5. Antipsychotic as risk factor for metabolic syndrome 6. Antipsychotic: Clozapine 
in severe mental illness in forensic setting 7. Antipsychotic: Haloperidol in severe mental 
illness in forensic setting 8. Severe mental illness as a risk factor for metabolic syndrome 9. 
Mood disorders and metabolic syndrome 10. Guidelines for screening of metabolic syndrome 
for second generation antipsychotics 11. Monitoring for detection of metabolic syndrome in 
severe mental illness on antipsychotics 12. Metabolic monitoring  of clozapine in South Africa                                                                                                                             
 
The search included key words: Severe mental illness” “schizophrenia” “schizophrenia 
spectrum disorders” “schizoaffective disorders” “Clozapine” “haloperidol” “sodium 
valproate” “diabetes mellitus OR “hyperglycaemia” OR “impaired glucose tolerance” OR 
”fasting glucose” “hypertension OR “high blood pressure”, “obesity” OR “overweight” OR 
“body mass index” OR “”BMI “,”Hypercholesterolemia” OR “Hyperlipidaemia” OR “high 
cholesterol” OR “dyslipidaemia”  Metabolic Syndrome” “monitoring” “forensic sciences OR 
forensic hospitals”  
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The following databases were searched: Medline, PubMed, and Scopus, EBSCO Host (Africa 
Wide Information, CINAHL, Psych ARTICLES, and Psych INFO). Other articles were also  
retrieved by looking at the authors of the references. A limitation was that some of the 
articles were not in English or they could only be accessed with a fee and therefore only 
abstracts could be obtained. Studies on paediatric populations were excluded. 
 
INTRODUCTION 
1. CARDIOVASCULAR MORTALITY AND SEVERE MENTAL ILLNESS 
Cardiovascular mortality is a global priority health concern causing an estimated 17.5 million 
deaths in 2012 which represents 31% of worldwide deaths (1). A systemic analysis on the 
Global Burden Disease Study during the period 1990-2013 shows that Sub Saharan Africa has 
registered one million cardiovascular deaths which contributes to 5.5% of the global 
cardiovascular deaths(2).  
Cardiovascular mortality is a significant cause of premature mortality in patients with severe 
mental illness compared to the general population (3).Severe mental illness refers to a broad 
range of major psychiatric disorders such as schizophrenia spectrum disorders, mood 
disorders and other psychotic disorders which cause impaired functioning at work and socially 
(4). The literature has shown that patients with severe mental illness have a shorter life 
expectancy due to cardiovascular events (3,4,5).  A review by Azad and colleagues in 2016 
showed that patients with schizophrenia have a reduced lifespan by 15-20 years compared to 
the general population, with cardiovascular deaths as the main cause of death surpassing 
suicide (3). 
According to the World Health Organisation, there are various risk factors associated with 
cardiovascular deaths, divided as modifiable and non-modifiable factors. Lifestyle modifiable 
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risk factors include smoking, alcohol abuse, poor physical activity and diet which exist across 
all the range of psychiatric diagnosis. Patients who are diagnosed with schizophrenia have a 
higher rates of smoking, poor diet and sedentary lifestyle. They are sedentary for around 11 
hours per day, consume 400 calories more than the general population. 1 in 5 patients have 
or have had alcohol use disorder(5). 
2. METABOLIC SYNDROME IN SEVERE MENTAL ILLNESS 
Definition of metabolic syndrome 
 
Metabolic syndrome (MS) is a cluster of cardiovascular risk factors which include 
hyperglycaemia, obesity, dyslipidaemia (hypertriglyceridemia and low high density 
lipoprotein( HDL) and hypertension leading to cardiovascular deaths (6).It is a worldwide 
epidemic according to the International Diabetes Federation with a prevalence of 20-25% in 
the general adult population(7). Metabolic syndrome was first described as Syndrome X. Over 
the years, metabolic syndrome has been defined in various ways. There are now different 
diagnostic criteria for metabolic syndrome based on the World Health Organisation (WHO) in 
1998, the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP III) 
in 2001 and modified in 2003 (modified NCEP ATP III), the International Diabetes Federation 
(IDF) criteria in 2006, and the Joint Interim Statement (JIS) in 2009 (6,7,8).The diagnostic 
criteria have similar core components with variation on diagnostic cut off values and the 
requirement of absolute or non- absolute criteria (6). Unfortunately, with the various 
definitions of metabolic syndrome, it has become more difficult to use a simple screening 
method to determine the prevalence rates in different population (6).   
 
Table 1 shows the difference in criteria for the widely used definitions of metabolic 
syndrome (8).  
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Table 1. Fully adapted from*   Anagnostis P. Metabolic syndrome in the Mediterranean region: 
Current status. Indian Journal of Endocrinology and Metabolism. 2012; 16(1):72-80. 
 
3. Mechanisms of metabolic syndrome 
Insulin resistance contributes largely to the pathophysiology of metabolic syndrome. Insulin 
resistance is defined as high plasma insulin which is unable to maintain normal plasma glucose 
(9). 
Obesity:  An increased in free fatty acids is a major contributor to metabolic syndrome. An 
increase in intra abdominal fat also causes an increase in fatty acids to the liver and can also 
affect insulin resistance (8). 
Dyslipidaemia: Lipid metabolism involves the formation of VLDL (Very Low Density 
lipoprotein)  from the liver. The triglycerides are transported via VLDL and are metabolised to 
produce IDL (Intermediate Density lipoprotein) which then form LDL (low density lipoprotein).  
LDL is characterised as the bad lipoprotein (pro atherogenic). HDL is the good lipoprotein(anti 
atherogenic) which carry fat molecules from the body cells to the liver (8). 
Elevated triglycerides is a feature of metabolic syndrome and reflects insulin resistance. The 
other feature is low high-density lipoprotein (HDL) cholesterol when there is the presence of 
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hypertriglyceridaemia which is due to a reduction in the cholesteryl ester content of the 
lipoprotein core. The composition of small dense low-density lipoprotein (LDL) cholesterol is 
predominant when it is associated with elevated triglyceride and low HDL cholesterol .High 
LDL level is associated with higher risk of myocardial infarction (8). 
Hypertension: There is a known risk between insulin resistance and hypertension (8). 
4. Prevalence of metabolic syndrome and its associated risk factors 
There is progressive evidence in various studies that people with serious mental illness have 
an increased risk for metabolic syndrome with prevalence ranging from 28.7% to 60% (10-
14). One large scale meta-analysis by Mitchel et al. (2013) showed an overall prevalence of 
32.5% in schizophrenia patients using any standardised criteria (NCEP ATP III, NCEP ATP III 
modified, IDF) for metabolic syndrome. Although that study looked at the prevalence among 
27 countries, South Africa was not included in the meta-analysis, which limits our data on the 
prevalence of metabolic syndrome in South Africa. Mitchell et al. also looked at each 
individual parameter of metabolic syndrome. The proportion of overweight using the NCEP 
ATP was 49.4% and 44.4% using the IDF criteria. The rate of hyperglycaemia was 19.5% using 
the NCEP ATP III (Fasting blood sugar >110mg/dl) and 18.8% using NCEP ATP III modified. The 
prevalence of hypertriglyceridemia was 39.3%, low HDL 42.6%, hypertension was 38.7% and 
diabetes was 10.9% using any standardised criteria (15). Several studies have reported on 
different risk factors of metabolic syndrome (16-18). In the meta-analysis by Mitchell et al., 
older age (>55 years) and longer duration of illness (7.8 years) was associated with increased 
risk for metabolic syndrome whereas gender was not identified as a risk factor for metabolic 
syndrome (15). However, there is mixed data on the prevalence rates of metabolic syndrome 
by gender with evidence from another systematic review by Papanastasiou (2013) showing 
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an increased prevalence of metabolic syndrome in females (16). A few other studies included 
in the meta-analysis report increased prevalence in males or no difference (16). There are 
limited studies looking at ethnicity of patients with metabolic syndrome in high income 
settings. A few studies showed that Hispanics have higher rates of metabolic syndrome, 
however no accurate conclusions can be drawn from the limited data (10). Other populations 
who have a predisposition to increased risk of metabolic syndrome at a lower body mass 
index and waist circumference are Indians and Asians (19). In South Africa, Indian ethnicity 
was a significant risk factor for metabolic syndrome in a local psychiatric outpatient setting in 
Kwazulu Natal (17). In contrast, one other study outside the African context showed that 
Indians and Asians with mental illness had a lower prevalence of metabolic syndrome, which 
can be attributable to use of prescribing more typical antipsychotics than atypical 
antipsychotics with typical antipsychotics known to have less risk for metabolic syndrome 
(17). 
 
In our resource limited settings in South Africa, there are few studies on metabolic syndrome. 
There is one cross sectional study which has been done on outpatients with severe mental 
illness in KwaZulu Natal, South Africa. This study looked at the prevalence of metabolic 
syndrome in South African patients with severe mental illness of different ethnic groups. 
Patients with severe mental illness of Indian descent had a higher prevalence of metabolic 
syndrome (60%) as compared to African patients with a prevalence of 19.4%. The other risk 
factors apart from Indian ethnicity were female gender. Young patients under 25 years old 
with serious mental illness also showed an increasing risk for metabolic syndrome. There was 
significant increased waist circumference (55.1%) and low HDL cholesterol (52.5%) in patients 
with severe mental illness compared to the control group with no severe mental illness (17). 
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In another study in South Africa, the prevalence of metabolic syndrome in severe mental 
illness was higher in Black African females (37.7%) compared to Black African males (10,3%), 
further supporting the evidence that female gender is a risk factor for metabolic syndrome 
(20). 
A cross sectional study done at Westkoppies Hospital, South Africa looked at the prevalence 
of metabolic disorders: metabolic syndrome, hypertension, diabetes mellitus, total 
cholesterol dyslipidaemia, triglyceride dyslipidaemia, Low density lipo-protein (LDL) 
cholesterol dyslipidaemia, overweight and obesity in 84 long term psychiatric inpatients 
which excluded forensic patients. The prevalence of metabolic syndrome using the NCEP ATP 
III criteria was 32%. The prevalence of each metabolic disorder are : hypertension 32% in 
which 41% of the hypertensive patients were newly diagnosed , diabetes mellitus 8%, 
cholesterol dyslipidaemia 32%, triglyceride dyslipidaemia 29%, low density lipoprotein (LDL) 
dyslipidaemia 50%, overweight 37%, and obesity 24%. There were 96% patients newly 
diagnosed with dyslipidaemia (16).  
 
5. Antipsychotics as risk factor for metabolic syndrome 
Antipsychotics form the mainstay of treatment for severe mental illness, referred to as first 
generation antipsychotics (FGA) or typical antipsychotics and second-generation 
antipsychotics (SGA) or atypical antipsychotics. Second generation antipsychotics have been 
associated with greater risk of metabolic syndrome (21). Various studies showed that 
clozapine and olanzapine are among the second-generation antipsychotics associated with 
the highest risk of metabolic syndrome (12, 20-22). In one retrospective study, second 
generation antipsychotics were associated with a threefold increased risk of metabolic 
syndrome compared to first generation antipsychotics (22). In one of the largest clinical trials, 
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the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study trial , the 
prevalence of metabolic syndrome was highest (34.8-43.9%) in patients on olanzapine (12). 
In the meta-analysis by Mitchel et al, patients who were on clozapine had the highest rate of 
metabolic syndrome at 51.9%. However the patients on clozapine were older with long 
duration of illness and had previous exposure to antipsychotics which can contribute to the 
high rate of metabolic syndrome (15). 
 
First generation antipsychotics which include haloperidol are not without risk for metabolic 
syndrome. However, there are also no meta analyses comparing the risk of the various first 
generation antipsychotics associated with metabolic syndrome (15). In the CATIE study the 
first generation antipsychotic used was perphenazine, which is not being used in South Africa 
and also showed no significant risk of metabolic syndrome (12).  A South African study has 
demonstrated that patients with schizophrenia who received 12 months of first generation 
long acting injectable flupenthixol decanoate still reported significant  increases in weight and 
increased in triglycerides (TG)  and  reductions in HDL with an increase in the TG/HDL ratio 
which are metabolic parameters predisposing to cardiovascular events (23). 
 
In the study in Kwazulu Natal , South Africa by Saloojee (17), there was no statistical difference 
in rates of metabolic syndrome between first and second generation antipsychotics, or 
between monotherapy versus polytherapy (combination of 2 or more antipsychotics and/or 
sodium valproate and antidepressants). However, a limitation of that study was that there 
were only 29 patients on clozapine and 13 patients on olanzapine. Both drugs are second 
generation antipsychotics known to have higher risk of metabolic syndrome, and therefore 
the results might not be a true reflection of the risk of metabolic syndrome (17). In another 
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study, clozapine as monotherapy was associated with higher risk of metabolic syndrome than 
polytherapy with 2 or more first generation antipsychotics (28.6% vs. 70.4%, p=0.004) (24).  
 
6. Antipsychotic: Clozapine in severe mental illness in forensic setting  
Clozapine, a second generation antipsychotic with high risk of metabolic syndrome is the drug 
of choice used in schizophrenia patients who are resistant to treatment to other 
antipsychotics (25). Clozapine is therapeutically superior to atypical antipsychotics in patients 
with better improvement in positive and negative symptoms (38, 40). It is also effective to 
reduce suicide, self-injurious behaviour and aggressive behaviour (26). 
 
There are only a few studies about metabolic syndrome in forensic patients. Clozapine was 
widely used in forensic patients in New South Wales to reduce violence and suicide rates. 
Forensic patients carry a risk of cardiovascular mortality due to limited physical activity in 
hospital, however there is minimal research on these patients physical health.  One study in  
a 160 bed forensic hospital in Toronto showed that the 22% of the patients met the criteria 
for metabolic syndrome (43,44). 
 
7. Haloperidol in severe mental illness  
Haloperidol, a first-generation antipsychotic is widely used but has an increased risk of 
extrapyramidal side effects (EPSE). Haloperidol is also commonly used for agitated and violent 
patients (46). In a Cochrane review, haloperidol was superior to placebo for the treatment of 
schizophrenia but with high propensity for EPSE. In  randomised clinical trial with patients 
from Veterans medical centres with a diagnosis of treatment resistant schizophrenia were 
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assigned to either clozapine group or the haloperidol group, it was concluded that clozapine 
was more effective than haloperidol with fewer EPSE and spent fewer days in hospital (27). 
 
8. Severe mental illness as a risk factor for metabolic syndrome 
The risk of metabolic syndrome in severe mental illness is not only associated with 
antipsychotics, but with the interplay of multifactorial factors ranging from genetic factors to 
poor lifestyle, to the severe mental illness itself (1, 28, 29). Metabolic abnormalities have been 
found to be present at the start of psychotic symptoms of schizophrenia, indicating that 
metabolic disturbances are part of the illness and not due to treatment alone (29). Insulin 
resistance is present at an early age of 25 in patients with mental illness (30). There is also 
evidence of impaired fasting glucose in patients with first episode schizophrenia who have 
not  started antipsychotics (31). Further evidence is the presence of Type 2 Diabetes mellitus 
in 18-30% of first degree relatives of people with schizophrenia (32). However, there are 
inconsistent results regarding hypertension and lipid abnormalities present in schizophrenia 
prior to starting antipsychotics (28). The above evidence suggests that the association 
between metabolic syndrome and schizophrenia is not only due to antipsychotics use. The 
link between schizophrenia and diabetes mellitus was long established by Maudsley in 1879 
prior to the introduction of antipsychotics (30). 
 
Genetic factors play a role in developing metabolic syndrome in schizophrenia. Several genes 
such as fat mass and obesity associated gene (FTO), leptin and leptin receptor genes (LEP, 
LEPR), methyl tetrahydrofolate reductase (MHTFR) and serotonin receptor 2 gene (HTR2C) 
have been hypothesised to be implicated in metabolic syndrome. Schizophrenia and 
metabolic syndrome has also been hypothesised to share the same pathophysiology of 
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inflammation which can be another contributing factor (33). Other factors classified as 
modifiable are poor diet and exercise, alcohol and smoking in patients with severe mental 
illness. Patients with schizophrenia smoke at least two to three times more than the general 
population (34).  
 
9. Mood disorders and metabolic syndrome 
There are few studies that compared the prevalence of metabolic disorders among various 
psychotic and mood disorders. A recent meta analysis which included 7616 patients who had 
a diagnosis of  schizoaffective disorder , schizophrenia and other non affective psychosis 
showed a higher rate of metabolic syndrome in individuals with schizoaffective disorder Odds 
Ratio 1.41 (95% CI (1.23-1.61) for Metabolic syndrome as compared with schizophrenia and 
other non affective psychosis (35).  
 
The CLAMORS (The Cardiovascular, Lipid and Metabolic Outcomes Research in Schizophrenia 
Study) has shown that patients with schizoaffective patients had a higher prevalence of the 
metabolic syndrome compared with schizophrenia (24.6% in schizophrenia patients vs 25.6% 
in schizoaffective patients. 43.3% of the schizoaffective patients were on antidepressant 
treatment in comparison to 25.2% of the patients with schizophrenia. The possible 
explanation is the presence of affective and psychotic symptoms with use of antidepressants 
and mood stabilisers which increase the risk of metabolic syndrome.(36) 
Antipsychotics are usually prescribed together with mood stabilisers which have an additive 
effect on metabolic syndrome. The two most common mood stabilisers used are lithium and 
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sodium valproate. The latter causes a mean weight gain of 6.4 kg over 3 months, increased 
risk of insulin resistance and type 2 diabetes (5). 
 
10. Guidelines for screening of metabolic syndrome for second generation 
antipsychotics 
There are various guidelines published for the monitoring of metabolic syndrome in patients 
prescribed antipsychotics. They are the South African Society Treatment Guidelines, 
Maudsley Guidelines, American Diabetes Association with the American Psychiatric 
Association and the National Institute of Clinical Excellence (NICE) guidelines (31, 32, 33, and 
34). 
 
In 2005 the South African Society Treatment Guidelines recommend a baseline body mass 
index (BMI) and waist: hip ratio, fasting blood glucose, full blood count , liver function tests 
and baseline ECG (if cardiovascular risk) before starting antipsychotics. 
Table 2 with summary of the guidelines for monitoring metabolic syndrome for patients on 
antipsychotics 
 ADA/APA/2004 Maudsley Guidelines 
/2012 
SASOP Guidelines 
(South African 
Guidelines) 
Personal/Family 
History 
Baseline and annually       
Weight/BMI Baseline, 4 weeks, 12 
weeks, quarterly 
Baseline, 1 month, 3 
months, 4-6 months 
and at 12 months, 
Baseline BMI and 
waist circumference 
Waist 
circumference 
Baseline and annually Baseline, 1 month, 3 
months, 4-6 months 
and at 12 months, 
Baseline 
 
Blood pressure 
Baseline, 12 weeks 
and annually 
Baseline, frequently 
during titration 
Baseline 
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A meta-analysis by Hert et al (2011) looked at all the guidelines on screening for metabolic 
syndrome and found that 4 of the 18 guidelines identified were recommended.  Most of the 
guidelines did advise for the monitoring of weight, Body Mass Index, waist circumference, 
blood pressure, fasting lipids and glucose although at different time intervals) with 
recommendation for monitoring of cardiovascular risk factors usually first at baseline, then 6 
weeks, 12 weeks and annually thereafter (37). 
 
11. Monitoring for detection of metabolic syndrome in severe mental illness on 
antipsychotics 
In the CATIE study, 20% of the patients with schizophrenia had hypertension and 11% of 
patients had diabetes mellitus at baseline. There were high rates of non-detection: 30.2% for 
diabetes, 62.4 % for hypertension and 88.0% for dyslipidaemia in patients who were not 
receiving treatment for their chronic disease (12). 
 
Despite the high prevalence of metabolic syndrome, there is low rates of monitoring of 
metabolic parameters. A meta-analysis across five different countries showed that the 
screening for metabolic syndrome remained low in patients on second generation 
antipsychotics, with only 56.1% of patients tested for glucose and 28.9% of patients tested 
for lipids after implementation of guidelines (38). Similarly after the American Diabetes 
Fasting lipids Baseline, 12 weeks 
and annually 
Baseline, 12 weeks 
and annually 
Baseline 
Fasting glucose Baseline,12 weeks and 
every 5 years 
Baseline, 12 weeks 
and annually 
Baseline 
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Association’s Consensus Statement on Antipsychotic Drugs the baseline glucose test was 
21.8% and lipid testing was 10.5% in another study in the United States (39).The highest rate 
of monitoring of risk factors for metabolic syndrome was among the Veteran population, 
where 80% of veterans with severe mental illness were screened for all the parameters of 
metabolic syndrome. However Veterans are not a true reflection of the general population as 
they had greater access to medical health care and strict monitoring programmes (40). There 
were improved monitoring rates of glucose and lipids in a minority population with 
schizophrenia who were on medical aid in Kansas, United States (41).  
 
Monitoring across different countries has been poor (38). A study in UK among 106 
outpatients with predominant Caucasian population showed that there was poor monitoring 
across all metabolic parameters with no patient monitored for Body mass index and waist 
circumference (42). 
 
12. Metabolic monitoring  of clozapine in South Africa                                                                                                                                                                                                                                                            
There are few studies looking specifically at metabolic syndrome in patients prescribed 
clozapine. In a study in South Africa, clozapine use was studied in Xhosa patients. It was a very 
small study of 29 patients that looked at prevalence of metabolic syndrome in outpatients on 
clozapine. It is the first study on a particular race of patients in South Africa. Metabolic 
syndrome was present in 45% of patients, with 69% of the patients having a family History of 
cardiovascular disease which could contribute to the risk of metabolic syndrome. 13% of the 
patients had undiagnosed diabetes mellitus. The mean waist circumference was 95.6cm 
which is above the waist circumference according to IDF criteria and showed the presence of 
obesity in this population (43). 
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Similarly in an outpatient clinic at Kwazulu Natal looking at screening of individual metabolic 
parameters of metabolic syndrome for patients prescribed antipsychotics, it  was found that 
only 2 patients out of 331 participants (1%) were screened for all parameters of metabolic 
syndrome.  Antipsychotics was not exclusive to clozapine. The clinic was measuring blood 
pressure in 99% of patients. There was also poor monitoring of fasting blood glucose (3.9%) 
and lipids (1.8%) for patients. For patients on clozapine and olanzapine, the medications with 
the highest metabolic risks, less than 10% were tested for fasting blood glucose and lipids. 
This was the study with the lowest rate monitoring in the literature, and waist circumference 
was the least measured variable (0.6%). (44).Waist circumference is a simple screening tool 
and is a useful predictor for metabolic syndrome with a sensitivity of 79.4% and a specificity 
of 78.8% (15). Despite waist circumference replacing body mass index in all definitions of 
metabolic syndrome as it has a better correlation with metabolic syndrome (7), it is poorly 
documented as evident by several studies both in high income and low income countries (15, 
44).   
 
Waist circumference in one study was shown be a good predictor for insulin resistance in 
schizophrenia patients who were on clozapine (45). In a rural South African community, the 
waist circumference which could predict the presence of at least two other components of 
the metabolic syndrome was 86 cm for men (sensitivity 61.2%, specificity 82.9%) and 92 cm 
for women (sensitivity 45.9%, specificity 81.9%). Elevated waist circumference was highly 
prevalent in this population with more than 90% of the patients who had elevated waist 
circumference had metabolic syndrome (46) 
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AIMS AND OBJECTIVES 
 The aim of this pilot study is to determine the prevalence of metabolic disorders and 
investigate the associated risk factors of metabolic disorders in forensic patients with 
schizophrenia spectrum disorders who are on clozapine compared to patients on haloperidol. 
 
Objectives: 
1) To establish if there is annual screening of metabolic disorders in forensic patients 
with schizophrenia spectrum disorders who are on clozapine and haloperidol for at 
least one year duration. 
2) To determine the prevalence of metabolic disorders in forensic patients with 
schizophrenia spectrum disorders who are on clozapine compared to haloperidol. 
3) To determine the relationship between metabolic disorders and the clinical and 
demographic risk factors in forensic patients with schizophrenia spectrum disorders 
who are on clozapine compared to haloperidol. 
 
LIMITATIONS OF LITERATURE AND MOTIVATION FOR STUDY  
 There is limited research exploring the prevalence and associated risk factors of metabolic 
disorders in severe mental illness in South Africa with no research done on forensic patients. 
This sub-population bear exceptional vulnerability to metabolic disorders and cardiovascular 
mortality and therefore requires metabolic screening.  
 
If there is more screening and detection, there will be improved medical care of forensic 
patients and reduced burden of cardiovascular mortality and health costs in the midst of an 
obesity epidemic in Sub Saharan Africa. 
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Secondly, there are no studies with clear associations of the causative factors of metabolic 
syndrome in schizophrenia spectrum disorders both in high income settings and low income 
settings. 
 
 To our knowledge this is the first South African study examining the prevalence and 
associated risk factors of metabolic disorders in schizophrenia spectrum disorders 
comparing clozapine, widely used antipsychotic in treatment schizophrenia spectrum 
disorders in forensic patients with high risk of metabolic syndrome to haloperidol which is 
least associated with metabolic syndrome. 
 
This pilot study will subsequently address the overriding need to assess the prevalence of 
metabolic syndrome in the forensic population because it is a potentially life-threatening 
illness that is not being monitored adequately. 
CHAPTER 2: METHODS 
 
STUDY DESIGN 
The study is a retrospective folder review. 
 
STUDY SETTING 
The study was conducted in the Forensic Mental Health Service at Valkenberg Hospital, 
Cape Town, Western Cape South Africa.  
STUDY POPULATION 
They are forensic patients who have been recruited from Valkenberg Hospital from ward 11, 
12, and ward 20.  A sample of 45 participants on clozapine was used for the study group, 
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and 23 participants who are on haloperidol for the comparison group. The comparison 
sample was limited by the number of patients who were on haloperidol. 
Inclusion criteria:  
1) Participants are forensic patients at Valkenberg Hospital. 
2) All participants are males. 
3) All Participants are adults >18 years. 
4) Participants have a clinically documented primary diagnosis within the schizophrenia 
spectrum disorders which include either brief psychotic episode, schizophreniform, 
schizophrenia , schizoaffective disorders or delusional disorder. 
5) Participants can have comorbid psychiatric diagnosis of substance use disorder or 
personality disorder. 
6) In the study group, participants have been on clozapine for at least one year as at 30th 
April 2017 as monotherapy or combined with another psychotropic or chronic 
medications except haloperidol. 
7) In the comparison group, participants have been on haloperidol for least one year as 
at 30th April 2017 or combined with another psychotropic or chronic medications 
except clozapine. 
8) The use of any concurrent medications which include other antipsychotics, mood 
stabilisers, antidepressants, anti cholinergics and benzodiazepines are included in 
both study and comparison group 
9) Participants can have any comorbid medical condition. 
10) The use of any comorbid chronic medications for chronic disease are included in both 
study and comparison group. 
Exclusion criteria: 
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1) Participants who are on both clozapine and haloperidol.(This is not common 
practice). 
2) Female patients (There are only male patients in the forensic setting at Valkenberg 
Hospital) 
3) Participants who can’t give informed consent. 
4) Participants who refuse to participate in study. 
DATA COLLECTION 
The folders numbers of forensic patients who are on clozapine (study group) and 
haloperidol (comparison group) were obtained from the pharmacy at Valkenberg Hospital. 
- Baseline data on demographics (age, marital status, ethnicity, level of education, 
employment and grant status), psychiatric diagnosis, medical comorbidities, past 
family history, and criminal offenses was obtained from patients folders. 
- Baseline data on Blood pressure, weight, Body mass index, waist circumference was 
extracted from the nursing folders and patients folders. 
- Baseline data on fasting lipids and fasting glucose were obtained from the National 
Health Laboratory Service (NHLS) on the website www.trackcarelabwebview.nhls.ac.za 
or the patient’s folder.  
- Baseline data on medications was obtained from prescription charts and the 
patient’s folder. 
- The data on blood pressure, weight, body mass index, waist circumference, fasting 
lipids and glucose was obtained as from 30th April 2016 to 30th April 2017 over a one-
year period.  The latest data was collected from the relevant folders. 
 The following variables was obtained from the relevant folders using a data collection form 
(Appendix 1): Commented [MH1]: NO – DO NOT HAVE IT AS BULLET 
POINTS – NEED TO WRITE IN SENTENCES 
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1) Demographic data: 
 Age 
 Marital status 
 Ethnicity  
 Level of education 
 Employment status and grant status 
 
2) History of smoking 
3)  Psychiatric Diagnosis: 
 Schizophrenia spectrum disorders: schizophrenia, schizoaffective Disorder, 
schizophreniform disorders, delusional disorder, brief psychotic Disorder. 
 Age at diagnosis 
 Duration of illness 
 
3) Psychiatric Treatment 
 Study group: Duration of clozapine use, dosage of clozapine. 
 Comparison group: Duration of haloperidol, dosage of haloperidol. 
 
 Other antipsychotics in combination:  
               First generation antipsychotics 
Depot antipsychotics 
Second generation antipsychotics 
 
 Other medications in combination: 
Mood stabilisers 
Antidepressants 
Benzodiazepines 
Anticholinergics 
Other medications 
 
4) Medical treatment 
 Antihypertensive  
 Hypoglycaemics or insulin therapy 
 Statins  
 Antiretrovirals 
 Other medical treatment 
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5) Comorbidities 
 Diabetes mellitus 
 Hypertension 
 Hyperlipidaemia 
 HIV disease 
 Other comorbidities 
 
6) Family history of medical/psychiatric illness 
7) Offense 
Murder 
Physical assault 
 Sexual assault 
Others 
 
8) Metabolic parameters: 
The latest data that has been documented will be taken for this study over a one 
year period from 30th April 2016 to 30th April 2017. 
 Weight in kg 
 Body Mass index (kg/m2)  
 Waist circumference (cm) 
 Blood pressure (mm/Hg) 
 Fasting blood glucose(mmol/l) 
 Fasting lipids (mmol/l)  
      Total cholesterol 
Triglycerides 
 HDL cholesterol 
 LDL cholesterol 
 
DEFINITION CRITERIA  
For the purpose of this study, the following was defined for metabolic disorders. Patients 
are defined as having a metabolic disorder if they had a documented diagnosis and 
treatment for one of the disorders and/or met criteria for one of the definitions of the 
disorder(Table 3). Commented [MH2]: shown where?? 
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Table 3: Fully Adapted from Maaroganye K, Mohapi M, Kruger C, Rheeder P. The prevalence 
of metabolic syndrome and its associated factors in long-term patients in a specialist 
psychiatric hospital in South Africa: original. African journal of psychiatry. 2013; 16(6):414-
23. 
Metabolic syndrome 
NCEP-ATP III 
Three or more of the following five risk factors: fasting blood glucose ≥5.6 
mmol/l (100 mg/dl), BP ≥130/85 mmHg, fasting triglyceride ≥1.7 mmol/l (150 
mg/dl), high-density lipoprotein cholesterol <40 mg/dL (<1.03 mmol/L) in 
men and <50 mg/dL (<1.29 mmol/L) in women, waist circumference> 102 cm 
in men and waist circumference >88 cm in women 
Hypertension 2003 European Society of 
Hypertension (ESH) 
Systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg. 
Diabetes mellitus The 1998-1999 
European Diabetes Policy Group’s 
Confirmed fasting venous plasma glucose level above or equal to 7,0 mmol/l 
(>125 mg/dl) 
Total cholesterol dyslipidaemia Total cholesterol >5.2 mmol/l 
Triglyceride dyslipidaemia Triglycerides >1.7 mmol 
Low density lipo-protein (LDL) cholesterol 
dyslipidaemia 
LDL cholesterol >3.4 mmol/l 
Overweight WHO definition Body mass index (mass/height²) ≥ 25 
Obesity WHO definition  Body mass index (mass/height²) ≥ 30 
 
DATA ANALYSIS 
All analyses were performed using SPSS version 24.  It stands for Stastical Package for Social 
Sciences used for statistical analysis.  Unless noted otherwise, the threshold for statistical 
significance (α) will be set at .05. For each of the analyses described below, we calculated 
the appropriate effect size estimate, and interpreted these estimates following convention. 
Where assumptions underlying inferential statistical tests are violated, we will use the 
appropriate non-parametric tests. 
Descriptive statistics were used to describe continuous variables (mean, standard deviation, 
median) and categorical variables (counts). Normally distributed continuous data was 
analysed using student’s t- tests. Non-normally distributed data was analysed using the 
Kruskal Wallis tests or Wilcoxon rank sum test. Categorical variables were analysed using 
the Chi Square or Fischers test.  
The specific analyses used to answer our research questions were: 
Commented [MH3]: past tense – you’ve done this study 
already it is not your research proposal 
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(1) An independent sample’s t-test compared the prevalence of metabolic disorders 
in forensic patients with schizophrenia spectrum disorders who are on clozapine 
versus those on haloperidol. 
(2) Linear regressions were run to determine the relationship between clinical and 
demographic risk factors and the prevalence of metabolic disorders in forensic 
patients with schizophrenia spectrum disorders who are on clozapine compared 
to haloperidol. 
ETHICAL CONSIDERATIONS 
 
1) A written informed consent was obtained from each participant to access their 
medical data. (Informed consent as attached in Appendix 2)  
2) Each participant was anonymous. 
3) There was no coercion or financial incentive for participation. 
4) Participants had the right to refuse to participate in the study. 
5) Confidentiality was respected by assigning each patient a number on the data 
collection sheet. A separate file was kept with the patient’s name and folder 
number and stored in locked cabinet. 
6) All data were kept in a secured protected password computer for which only the 
investigator had access. 
7) The study involved minimal harm to the participants. 
8) This study was approved by the University of Cape Town, Human Research Ethics 
Committee, the National Department of Health and Valkenberg Hospital 
Research Committee. 
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CHAPTER 3: RESULTS 
The mean age of participants in the Study group was 42.69±11.78 years, and 39.96±10.29 
years in the Control group (t(66) = -0.943, p = .349).  Table 4 describes the demographic 
characteristics of both groups, and illustrates no significant between-group differences (all 
ps > .222).  
 
Table 4 
Demographic profile of patients in the Study and Control group 
 Study Group  
N = 45 
Control Group 
N = 23 
   
Variable n % N % χ2 p V 
Ethnicity     2.039 .361 .173 
Black 17 37.8 12 52.2    
Coloured 26 57.8 11 47.8    
White  2   4.4  0      0    
Employment     Fischer’s .316 .173 
Unemployed 43 95.6 18 85.7    
Employed  2   4.4   3 14.3    
Education     0.509 .775 .091 
Primary 13 32.5    7 33.3    
Secondary 23 57.5 13 61.9    
Tertiary  4 10.0  1   4.8    
Marital Status     Fischer’s .162 .279 
Single 36 81.8 20 90.9    
Married  2   4.5   1   4.5    
Divorced 6 13.6 0 0    
Widowed 0 0 1 4.5    
Smoker     Fischer’s .222 .171 
Yes 44 97.8 18 90.0    
No 1 2.2 2 10.0    
  
 
Patients in both groups had a range of psychiatric conditions, and were taking a range of 
medications (see Table 5).  Of note is that 95.7% of the Control group had schizophrenia 
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compared to 48.9% of the Study group, and 48.9% of the Study group had Schizoaffective 
Disorder compared to only 4.3% of the Control group (both ps <.001). Cannabis use was  
relatively high in both the Control and Study group (69.6% and 73.3% respectively). The 
most common medication used in the Control group was anticholinergics (30.4%), whereas 
the most common medication used by participants in the Study group was mood stabilizers 
(60%). 4 controls (33.3%) and 9 in the study group (42.9%) had a family history of a medical 
or psychiatric condition (χ2 (1) = 0.290, p = .719 V = .094).  
 
Patients in both groups had a similar number of psychiatric diagnoses, and the duration of 
psychiatric illness was not significantly different between the two groups (see Table 6). 
There were no significant differences in the duration of antipsychotic treatment between 
the Study group (who were all on Clozapine) and the Control group (who were all on 
Haloperidol).  
 
Table 7 represents the physiological profile of patients. There were no significant between-
group differences (all ps > .088), except that the Study group had a significantly higher 
weight compared to the Control group (p =.023). 
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Table 5 
Clinical profile of patients in the Study and Control group 
Variable Study Group  
N = 45 
Control Group 
N = 23 
   
 N % N % χ2 P V 
Psychiatric Diagnosis        
Schizophrenia 22 48.9 22 95.7 14.575 <.001* .463 
Alcohol use disorder 17 37.8 8 34.8 0.059 .809 .029 
Cannabis use disorder 33 73.3 16 69.6 0.107 .743 .040 
Methamphetamine use disorder 15 33.3 6 26.1 0.374 .541 .074 
Methaqualone use disorder 6 13.3 3 13.0 0.001 .973 .004 
Schizoaffective disorder 22 48.9 1 4.3 13.491 <.001* .445 
Antisocial Personality disorder 6 13.3 0 0 Fischer’s .089 .222 
Other diagnosesa 2 4.4 3 13.0 Fischer’s .327 .156 
Medication use        
Mood stabilizers 27 60.0 3 13.6 12.845 <.001* .438 
Antidepressants 3 6.7 1 4.3 Fischer’s 1.00 .047 
Benzodiazepines 1 2.2 0 0 Fischer’s 1.00 .086 
Anticholinergics 3 6.7 7 30.4 6.855 .009* .318 
Note. a2 participants in the Control group had intellectual disability, and 1 participant had psychosis due to HIV. 1 participant in the Study group had 
intellectual disability and another used Glue. 
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Table 6 
Clinical and treatment profile of participants  
 Study Group  
N = 45 
Control Group 
N = 23 
   
Variable Mean (SD) Range Mean (SD) Range t p d 
Number psychiatric diagnoses 2.67 (1.55) 0-6 2.52 (1.08) 1-5 -0.40 .690 0.11 
Duration of psychiatric illness(years) 14.11 (9.36)b 1-37 11.33 (8.48) 0.5-31 -1.20 .237 0.31 
Clozapine treatment 319.33 (118.99) 100-500 - - - - - 
Haloperidol treatment - - 2.78 (1.46) 0.5-5 - - - 
Duration antipsychotic treatment 
(years) 
4.59 (3.24)b 1-17 7.52 (5.46)c 1-18 331 .064 0.23 
aMann-Whitney U test performed. bData based on 44 participants. cData based on 21 participants.  
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Table 7 
Physiological measurements of patients in the Study and Control group 
 Study Group  
N = 45 
Control Group 
N = 23 
   
Variable Mean (SD) Range Mean (SD) Range t p D 
Systolic blood pressure (mmHg) 119.67 (14.57) 86-150 123.25 (12.94)g 95-143 0.95 .348 0.25 
Diastolic blood pressure (mmHg) 77.24 (11.18) 51-98 77.80 (12.87)g 50-97 0.18 .860 0.05 
Waist circumference (cm) 91.85 (12.80)a 70-121 85.85 (14.40)d 65-111 -1.31 .198 0.46 
Height (cm) 1.74 (0.07) 1.57-1.9 1.71 (0.07)h 1.59-1.85 -1.68 .097 0.43 
Weight (kg) 74.71 (15.41) 51-109.79 65.69 (11.91)g 52-95 -2.32 .023* 0.62 
Body mass index 24.67 (4.62) 16.4-36.3 22.60 (4.00)g 16.4-30.3 -1.74 .088 0.47 
Fasting blood glucose (mmol/l) 5.70 (3.48)b 3.8-17.5 4.55 (0.07)i 4.5-4.6 -0.45 .657 0.34 
Fasting HDL (mmol/l) 0.94 (0.26)c 0.62-1.46 0.74j - - - - 
Fasting LDL (mmol/l) 2.47 (0.53)d 1.64-3.41 2.62j - - - - 
Fasting total cholesterol (mmol/l) 4.33 (1.27)e 2.76-8.01 4.16j - - - - 
Fasting triglycerides (mmol/l) 2.47 (1.45)f 1-6.34 1.75j - - - - 
Note. aData based on 43 participants. bData based on 14 participants. cData based on 11 participants. dData based on 10 participants. eData based on 15 
participants. fData based on 13 participants. gData based on 20 participants. hData based on 21 participants. iData based on 2 participants. jData based on 1 
participant. 
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There were no significant between-group differences in terms of features of Metabolic 
Syndrome (see Table 8). However, although none of the Control group met the criteria for 
Metabolic Syndrome, 8 patients in the Study group did (χ2 (1) = 4.441, p = .035 V = .257)1. 
 
Patients on concurrent Clozapine and sodium valproate were compared to patients on 
Haloperidol. Again, while none of the patients on Haloperidol met the criteria for Metabolic 
syndrome, 6 (24%) of the 25 patients on concurrent Clozapine and sodium valproate did, (χ2 
(1) = 6.051, p = .023 V = .359). 
 
                                                        
 
 
 
37 
 
In terms of metabolic disorders, a significantly higher proportion of patients in the study 
group has hypertension and hyperlipidaemia (p = .003 and p = .021 respectively). 
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Figure 2 : Tests conducted for indicators of metabolic 
syndrome in study group
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Figure 3: Tests conducted for indicators of metabolic 
syndrome in control group
Proportion of sample who had tests done
38 
 
 A very low percentage of patients in both groups had tests conducted for fasting glucose, 
cholesterol, triglycerides, HLD and LDL (see Figure 1). Waist circumference was measured in 
95.6% of the study group compared to 43% of the control group. The measurements of 
weight, height and blood pressure is done in almost 100 % of the patients in the study 
group.  
 
Table 8 
Features of Metabolic Syndrome and metabolic disorders in the Study and Control group 
 Study Group  
N = 45 
Control Group 
N = 23 
   
 N % N % χ2 P V 
Metabolic Syndrome 8 17.8 0e 0 4.441 .035* .257 
Features of Metabolic Syndrome        
Elevated Triglycerides 6a 54.5 1h 100.0 - - - 
Elevated Waist circumference 14b 32.6 2g 20.0 0.607 .436 .107 
Elevated Blood pressure 9 20.0 4f 20.0 0 1.00 .00 
Decreased High Density low 
protein 
7a 63.6 1h 100.0 Fischer’s 1.00 .460 
Elevated Fasting Glucose 2j 14.3 0k 0 Fischer’s 1.00 .143 
Metabolic disorders        
Overweight 10 22.2 3f 15.0 0.451 .502 .083 
Obese 7 15.6 2f 10.0 0.358 .549 .074 
Diabetes 6 13.3 0i 0 Fischer’s .089 .222 
Hypertension 14 31.3 0i 0 9.011 .003* .364 
Hyperlipidaemia 9 20.0 0i 0 5.302 .021* .279 
Hypertriglyceridemia 1 2.2 0i 0 Fischer’s 1.00 .087 
TG dyslipidaemia 7c 53.8 1h 100.0 - - - 
Cholesterol dyslipidaemia 2d 13.3 0h 0 - - - 
LDL dyslipidaemia 12d 80.0 1h 100.0 - - - 
Number elevated features of MetS     8.718 .069 .361 
0 17  16 72.7    
1 14  4 18.2    
2 6  2 9.1    
3 5  0 0    
4 3  0 0    
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Note. 72.8% of the Control group had no features of MetS, 18.2% had 1 feature, and 2.6% had 2 
features. In contrast, 37.8% of the Study group had no features of MetS, 31.1% had 1 feature, 13.3% 
had 2 features, 11.1% had 3 features, and 6.7% had 4 features.  
aData based on 11 participants. bData based on 43 participants. cData based on 13 participants. dData 
based on 15 participants. eData based on 22 participants. fData based on 20 participants. gData 
based on 10 participants. hData based on 1 participant. iData based on 23 participants. jData based 
on 14 participants. kData based on 2 participants.  
 
 
Associations between metabolic features/disorders and demographic/clinical variables 
 
There were no significant associations within the Control group. Within the Study group, 
being on mood stabilizers meant patients were less likely to be overweight and more likely 
to be obese.  Patients with schizophrenia were less likely to be obese, whereas patients with 
schizoaffective disorder were more likely to be obese (see Table 9).   
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Table 9 
Associations (chi-square) between metabolic features/disorders and demographic/clinical variables 
Metabolic features 
and disorders 
Variable tested Odds ratio (95% CI) p Interpretation 
Overweight Mood stabilizer 0.196 .028 Those on mood stabilizers less likely to be 
overweight 
Obesity Schizophrenia Cannot be calculated – 
zero cell frequency 
.009 Patients with schizophrenia less likely to be 
obese 
Obesity Schizoaffective Cannot be calculated – 
zero cell frequency 
.004 Patients with schizoaffective disorder more 
likely to be obese 
Obesity Mood stabilizer Cannot be calculated – 
zero cell frequency 
.031 Those on mood stabilizers more likely to be 
obese 
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Correlational analyses 
 
Within both groups, there were significant positive correlations between age and duration 
of antipsychotic treatment (see Table 10).  
 
Within in the Control group only, there was a significant positive correlation between age 
and dosage of Haloperidol treatment. There was also a significant negative association 
between number of psychiatric diagnoses and duration of antipsychotic treatment (see 
Table 10).  
 
Within the Study group only, there was a significant negative association between age and 
number of psychiatric diagnoses (see Table 10). 
 
 Table 10 
Significant correlations between demographic and clinical variables 
 
Variable 1 
 
Variable 2 
Study Group Control Group 
R p r P 
Age Number psychiatric diagnoses -.315 .035 - - 
Age Dosage of Haloperidol treatment - - .423 .044 
Age Duration of antipsychotic treatment .350 .020 .679 .001 
Number psychiatric diagnoses Duration antipsychotic treatment - - -.445 .043 
 
CHAPTER 4: DISCUSSION 
This was the first South African study that investigated the prevalence of metabolic 
disorders and associated risk factors in forensic patients with schizophrenia spectrum 
disorders at Valkenberg Hospital. The primary aims were to determine (1) if there is annual 
screening of metabolic disorders in forensic patients with schizophrenia spectrum disorders 
who are on clozapine and haloperidol, (2) the prevalence of metabolic disorders and 
investigate the associated risk factors of metabolic disorders in forensic patients with 
schizophrenia spectrum disorders who are on clozapine compared to patients on 
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haloperidol, and (3) the relationship between metabolic disorders and the clinical and 
demographic risk factors in these patients. 
 
SCREENING OF METABOLIC SYNDROME 
A meta-analysis across five different high-income countries (United States of America (USA), 
United Kingdom (UK), Australia, Canada and Spain) showed a low screening rate for 
metabolic syndrome in patients taking antipsychotics with only 56.1% of patients tested for 
glucose and 28.9% of patients tested for lipids after implantation of guidelines (33). In South 
Africa, we have even a lower rate of screening of metabolic syndrome compared to high 
income countries. The screening of metabolic syndrome for patients with severe mental 
illness on antipsychotics in a South African outpatient clinic showed only 2 subjects (0.6%) 
out of 331 were screened for all five components of Metabolic syndrome. There was also 
reported low rates of testing with only 1.8% of patients tested for cholesterol and 3.9% for 
fasting glucose in patients (39).  
 
In the current study, the rates of screening in patients on Clozapine was higher for each 
metabolic component as compared to patients on Haloperidol (Figure 1). This may be 
because patients on Clozapine have a higher risk of developing metabolic syndrome, and 
therefore monitoring of metabolic parameters is especially important in this patient group. 
There also clear guidelines recommending monitoring of metabolic syndrome in patients on 
clozapine. The rates of screening for each metabolic component in the current study was 
higher than the Saloojee (2014) South African study. However, screening rates in current 
study are still low compared to higher income countries.  
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Overall a high proportion of patients in both groups had their weight, height and blood 
pressure measured, which is usually done on each admission of a patient. Although waist 
circumference is not routinely done, a high proportion of patients on Clozapine had this 
measurement (95%) compared to only 42% of patients on Haloperidol. Across both groups 
there as a very low rate of screening of blood tests: fasting glucose, cholesterol, 
trigylcerides, HDL or LDL (generally under 25% of patients had these measurements done). 
In summary, there is suboptimal screening of metabolic syndrome both in high income and 
low-income settings. In the current study less than 25% of all patients were fully screened 
for metabolic syndrome. Therefore, proper diagnoses and management of this syndrome 
cannot be established, and these tests should be routinely performed.  
The American Diabetes Association (ADA) and American Psychiatric Association (APA) 
guidelines need to be followed for monitoring patients on antipsychotics. 
 
Baseline 
4 
weeks 
8 
weeks 
12 
weeks 
Quarterly Annually 
Every 5 
years 
Personal/family historyb X     X  
Weight (body mass 
index) 
X X X X X   
Waist circumference X     X  
Blood pressure X   X  X  
Fasting plasma glucose X   X  X  
Fasting lipid profile X   X   X 
a 
 
Lifestyle modifiable risk factors should be addressed using the Diabetes Prevention Program 
as a guideline which recommends maintaining body weight or decrease by 5-7% of total 
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body weight, reducing calorie intake, more physical activity of 150 minutes of moderate to 
vigorous physical activity and light intensity activity and cessation of smoking (5). 
 
 
PREVALENCE OF METABOLIC SYNDROME AND METABOLIC DISORDERS 
Eight patients (17.8%) in the study group (Clozapine) met criteria for metabolic syndrome 
according to the NCEP-ATP III criteria and none of the patients in the control group 
(Haloperidol) did.  
 
The prevalence of metabolic syndrome in the current study is lower than the meta-analysis 
conducted by Mitchel et al. 2013 in which there was a 32.5% prevalence of metabolic 
syndrome in patients with schizophrenia who were on a range of antipsychotics. In the 
same meta-analysis, patients on clozapine had the highest rate of metabolic syndrome at 
51.9%. In a very small study that looked at prevalence of metabolic syndrome in outpatients 
on clozapine in Xhosa patients in South Africa, metabolic syndrome was present in 45% of 
patients (38). The prevalence of metabolic syndrome in the current study is lower than both 
of these studies in Pretoria with a prevalence of 32% in long terms psychiatric patients (15) 
and in Durban with a prevalence of 23.2% outpatients respectively (14). 
 
The lower prevalence of metabolic syndrome in the current study could be due to the 
inadequate screening of the syndrome, as we had very limited data on fasting glucose and 
cholesterol, both of which are key criteria for the diagnosis of metabolic syndrome. We 
would have expected a higher prevalence of metabolic syndrome on patients on clozapine 
compared to previous studies which looked at a range of antipsychotics as it is associated 
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with the highest risk of metabolic syndrome. However, our population of forensic patients is 
also a distinct group compared to other patients with mental illness as they are long term 
inpatients on a hospital diet and a routine schedule in ward. This may be an important 
factor since a bad dietary lifestyle is known to play a role in increasing the risk of metabolic 
syndrome (1). Our patients strict hospital diet may contribute to the lower prevalence of 
metabolic syndrome seen in our sample.  
 
In terms of metabolic disorders, a significantly higher proportion of patients in the study 
group had hypertension and hyperlipidaemia. Similarly, the CATIE study (9) also had 20% of 
patients with hypertension at baseline, and in the meta-anaylsis by Mitchel et al. (2013), the 
prevalence of hypertriglyceraemia was 39.3% and hypertension 38.7%.  
 
DEMOGRAPHIC RISK FACTORS FOR METABOLIC SYNDROME 
There are several risk factors for metabolic syndrome that were not investigated in the 
current study.  
First, our study population consisted of only male forensic patients at Valkenberg Hospital 
with schizophrenia spectrum disorders. Although it is the first study in South Africa to look 
at metabolic syndrome in forensic patients, other studies have found a significant 
association between female gender and having Metabolic syndrome (13,14).  
 
Second, the mean age of participants in the Study group was 42.69±11.78 years, and 
39.96±10.29 years in the Control group. However, it was shown that individuals with severe 
mental illness who older than 55 years have higher odds of having metabolic syndrome (15). 
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Third, our sample consisted of mainly Black and African male patients. In one study, it was 
shown that South Africans of Indian descent was a risk factor for metabolic syndrome 
among individuals with severe mental illness on antipsychotics (15). Furthermore, black 
females with severe mental illness have a higher prevalence of metabolic syndrome  
compared to black males(47). Since this study consisted of only male participants, such 
comparisons could not be made. 
 
Fourth, a family history of cardiovascular disease is a risk factor for cardiovascular deaths 
(1). However, this variable was poorly documented in the current study, and therefore we 
cannot comment on how this variable may play a role in the risk for developing metabolic 
syndrome.  
 
THE CLINICAL RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME 
This study looked at forensic patients with a diagnosis of schizophrenia spectrum disorders 
at Valkenberg Hospital. 
In this study, the most common diagnosis within the schizophrenia spectrum disorders was 
schizophrenia and schizoaffective disorders. Patients with a diagnosis of schizoaffective 
disorder were more likely to be on both a mood stabiliser and clozapine in the study group 
with a higher risk of metabolic syndrome. 
There is little research on mood stabilisers as a risk for metabolic syndrome compared to 
clozapine which is known to be associated with the risk of metabolic syndrome (13).  
This study had similar results to the CLAMORS ( The Cardiovascular, Lipid and Metabolic 
Outcomes Research in Schizophrenia Study)  which shown that patients with schizoaffective 
patients had a higher prevalence of the metabolic syndrome compared with schizophrenia 
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with the probable explanation that schizoaffective patients are on antipsychotics and also 
on mood stabilisers with increased risk of metabolic syndrome (36) . Sodium valproate used 
as a mood stabiliser in psychiatric disorders and in epilepsy has been associated with weight 
gain, obesity, hyperinsulinaemia and dyslipidaemia(48) . 
 
A first recent meta-analysis also showed that metabolic syndrome was higher in 
schizoaffective disorder than schizophrenia and other non-affective psychosis with an odds 
ratio of 1.41 95% CI (1.23-1.61) (35). Previous meta-analysis haven’t looked at the 
differences in metabolic syndrome between different disorders in the schizophrenia 
spectrum disorders. In this meta-analysis, it is hypothesised that the increased risk of 
metabolic syndrome in schizoaffective disorder can be due to different combination of 
antidepressants, mood stabilisers and antipsychotics which further increase the risk of 
metabolic abnormalities. However, there is no clear causal association between the 
diagnosis of schizoaffective disorder and the higher risk of metabolic syndrome which will 
require further research (43).  
 
LIMITATIONS 
 
It was a pilot study with a small sample size with retrospective study design. 
There were no female participants and the findings only apply to male patients. 
It was an underpowered study and intended only as a pilot study. 
 
CONCLUSION 
This study comprised only male forensic patients with schizophrenia spectrum disorders, 
using either clozapine or haloperidol. The prevalence of metabolic syndrome was higher in 
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the clozapine group than haloperidol group, which is unsurprising since clozapine is usually 
associated with a higher risk of metabolic syndrome. However, the prevalence on metabolic 
syndrome in this study sample was relatively low compared to other studies. This could be 
due to the low rate of screening of each criteria of metabolic syndrome. 
 There is a need for better screening of metabolic syndrome in forensic patients on 
antipsychotic treatment in South Africa. Further studies are needed to investigate the risk of 
metabolic syndrome for patients who are on a combination of clozapine and mood 
stabilisers as it represents a higher risk for metabolic syndrome. 
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APPENDIX 1 
DATA COLLECTION CAPTURE FORM (STUDY GROUP) 
 
 
 
DEMOGRAPHICS 
 
1. Sex 
      
 
2. Age          
18-25  
26-35  
36-50  
51-60  
>60  
 
3. Ethnicity 
 
White/Caucasian  
Black  
Indian/Asian  
Coloured  
Other  
Unknown/Missing  
 
4. Marital status 
 
Single  
Married  
Divorced  
Widowed  
Co habiting  
Unknown/Missing  
 
5. Educational level 
 
No school  
Primary school  
Secondary school  
Tertiary school  
 
 
6. Employment status 
 
Employed  
Unemployed On grant  Not on grant  
Date  
Patient number  
Ward  
Male  Female  
53 
 
7. SMOKING 
 
SMOKING YES                                     NO 
 
8. PSYCHIATRIC DIAGNOSIS 
 
Brief psychotic episode  
Delusional disorder  
Schizophreniform disorder  
Schizophrenia disorder  
Schizoaffective disorder  
Cormorbid psychiatric diagnosis  
Substance use disorder  
Personality disorder  
  
 
9. COMORBID MEDICAL CONDITIONS 
Diabetes mellitus  
Hypertension  
Hyperlipidaemia  
HIV disease  
Other medical comorbidities  
  
  
  
 
10. FAMILY HISTORY OF MEDICAL CONDITION/PSYCHIATRIC CONDITION 
Diabetes  
Hypertension  
Hyperlipidaemia  
Psychiatric condition  
Others(SPECIFY)  
 
 
11. TREATMENT (STUDY GROUP) 
 
 DRUG  Dosage  Duration of treatment 
CLOZAPINE   
  
 
12. TREATMENT 
 
OTHER DRUG DOSAGE 
CHLORPROMAZINE  
RISPERIDONE  
OLANZAPINE  
AMISULPIRIDE  
FLUPENTHIXOL DEPOT  
ZUCLOPENTHIXOL 
DECANOATE 
 
54 
 
FLUPHENAZINE 
DECANOATE 
 
OTHERS(specify)  
  
  
 
13. COMORBID MOOD STABILISERS 
LITHIUM  
SODIUM VALPROATE  
LAMOTRIGINE  
CARBAMAZEPINE  
Other mood stabilisers  
  
  
  
 
14. COMORBID ANTIDEPRESSANTS 
 
CITALOPRAM  
FLUOXETINE  
AMITRYPTILINE  
VENLAFAXINE  
OTHER ANTIDEPRESSANTS  
  
  
  
 
15. COMORBID BENZODIAZEPINES 
 
LORAZEPAM  
DIAZEPAM  
CLONAZEPAM  
  
  
  
16. COMORBID ANTICHOLINERGICS 
Orphenadrine  
  
 
17. OTHER CHRONIC MEDICATIONS 
  
  
  
 
 
18. OFFENSE 
MURDER  
PHYSICAL ASSAULT  
SEXUAL ASSAULT  
OTHERS(SPECIFY)  
55 
 
 
 
19. METABOLIC PARAMETERS 
 
 SCREENED(YES/NO) VALUE 
Weight(kg)   
Height(cm)   
Body Mass index(BMI) 
(kg/m2) 
  
Blood pressure(mm/Hg)   
Waist circumference (cm)   
Fasting glucose(mmol/l)   
Fasting lipids(mmol/l) 
       Total Cholesterol 
       Triglycerides 
       High Density protein(HDL) 
  
 
DATA COLLECTION CAPTURE FORM (COMPARISON GROUP) 
 
 
DEMOGRAPHICS 
 
1. Sex 
      
 
2. Age          
18-25  
26-35  
36-50  
51-60  
>60  
 
 
3. Ethnicity 
 
White/Caucasian  
Black  
Indian/Asian  
Coloured  
Other  
Unknown/Missing  
 
4. Marital status 
 
Single  
Married  
Date  
Patient number  
Ward  
Male  Female  
56 
 
Divorced  
Widowed  
Co habiting  
Unknown/Missing  
 
5. Educational level 
 
No school  
Primary school  
Secondary school  
Tertiary school  
 
 
 
6. Employment status 
 
Employed  
Unemployed On grant  Not on grant  
 
 
7. SMOKING 
 
SMOKING YES                                     NO 
 
8. PSYCHIATRIC DIAGNOSIS 
Brief psychotic episode  
Delusional disorder  
Schizophreniform disorder  
Schizophrenia  
Schizoaffective disorder  
Comorbid psychiatric diagnosis  
Substance use disorder  
Personality disorder  
  
 
                               
                                                           
9. COMORBID MEDICAL CONDITIONS 
Diabetes mellitus  
Hypertension  
Hyperlipidaemia  
HIV disease  
Other medical comorbidities  
  
  
  
 
10. FAMILY HISTORY OF MEDICAL CONDITION/PSYCHIATRIC CONDITION 
Diabetes  
Hypertension  
57 
 
Hyperlipidaemia  
Psychiatric condition  
Others(SPECIFY)  
 
 
11. TREATMENT (COMPARISON GROUP) 
DRUG  Dosage  Duration of treatment 
HALOPERIDOL   
 
 
 
DRUG DOSAGE 
CHLORPROMAZINE  
RISPERIDONE  
OLANZAPINE  
AMISULPIRIDE  
FLUPENTHIXOL DEPOT  
ZUCLOPENTHIXOL 
DECANOATE 
 
FLUPHENAZINE 
DECANOATE 
 
OTHERS(specify)  
  
  
 
12. COMORBID MOOD STABILISERS 
LITHIUM  
SODIUM VALPROATE  
LAMOTRIGINE  
CARBAMAZEPINE  
Other mood stabilisers  
  
  
  
 
13. COMORBID ANTIDEPRESSANTS 
 
CITALOPRAM  
FLUOXETINE  
AMITRYPTILINE  
VENLAFAXINE  
OTHER ANTIDEPRESSANTS  
  
  
  
 
14. COMORBID BENZODIAZEPINES 
 
LORAZEPAM  
DIAZEPAM  
58 
 
CLONAZEPAM  
  
  
  
15. COMORBID ANTICHOLINERGICS 
Orphenadrine  
  
 
 
 
16. OTHER CHRONIC MEDICATIONS 
  
  
  
 
 
17. OFFENSE 
MURDER  
PHYSICAL ASSAULT  
SEXUAL ASSAULT*  
OTHERS(SPECIFY)  
 
 
18. METABOLIC PARAMETERS 
 
 SCREENED(YES/NO) VALUE 
Weight(kg)   
Height(cm)   
Body Mass index(BMI) 
(kg/m2) 
  
Waist circumference(cm)   
Blood pressure(mm/Hg)   
Fasting glucose(mmol/l)   
Fasting lipids(mmol/l) 
       Total Cholesterol 
       Triglycerides 
       High Density protein(HDL) 
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APPENDIX 2 
         INFORMED CONSENT 
RESEARCH PROJECT FOR MMED PSYCHIATRY 
I, Dr Shazia Mungly will be looking at the physical effects of your medication: metabolic syndrome (a 
condition characterised by cluster of high sugar level, high blood pressure, obesity and high fat level 
in blood). You have already had the blood tests and treatment for your condition.  
I will be taking the information out of your folders but I will not be taking your name.  
Your information will remain confidential. 
You have the right to refuse participation in the study. 
I have read the above information, or it has been read to me. 
 I consent voluntarily to participate in this research. 
 
Name of participant:__________________                             Thumb print of participant(if unable to sign) 
    
Signature of Participant ___________________ 
 
Principle Investigator : Dr Shazia Mungly                      
Signature : …………………………………………….. 
Witness  name  : …………………………………….. 
Witness signature:……………………………………. 
Date:………………………………………………………… 
 
Appendix 3 : Ethics approval letter 
Appendix 4 : University of Cape Town Approval Letter 
Appendix 5: Department of Health Western Cape Approval Letter 
Appendix 6: Valkenberg Hospital Approval Letter 
 
